Wednesday, July 8, 2026

pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT

BridgeBio Oncology Therapeutics

News and analysis for BridgeBio Oncology Therapeutics on NovaPharmaNews — regulatory, clinical, and market coverage.

256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
Status
Public
HQ
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
Employees
103
Programs
34
Drugs
14
Patents
1
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning BridgeBio Oncology Therapeutics — regulatory, clinical, and market coverage.

News and analysis for BridgeBio Oncology Therapeutics on NovaPharmaNews — regulatory, clinical, and market coverage.

No coverage yet

We have not published news or analysis mentioning BridgeBio Oncology Therapeutics yet.

Back to company overview →